RoC review
This article was originally published in The Rose Sheet
Executive Summary
National Toxicology Program will accept comments on the "current process for reviewing nominations for listing in or delisting from the Report on Carcinogens and on the current listing criteria used for evaluating the nominations" at Jan. 27-28 meeting at the National Institutes of Health in Bethesda, Md., NTP announces in Dec. 3 Federal Register notice. Oral comments may be made during the meeting, while written comments submitted by Jan. 15 will be distributed to the panel and posted on the NTP RoC Web site prior to the meeting. An additional meeting will be held Jan. 29 to discuss the "NTP Vision for the 21st Century," a plan "to move toxicology from a predominately observational science at the level of disease-specific models to a predominately predictive science focused upon a broad inclusion of target-specific, mechanism-based, biological observations"...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.